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Abstract 
Spatio-temporal regulation of localised cAMP nanodomains is highly dependent 
upon the compartmentalised activity of phosphodiesterase (PDE) cyclic nucleotide 
degrading enzymes. Strategically positioned PDE-protein complexes are pivotal to 
the homeostatic control of cAMP-effector protein activity that in turn orchestrate a 
wide range of cellular signalling cascades in a variety of cells and tissue types. 
Unsurprisingly, dysregulated PDE activity is central to the pathophysiology of many 
diseases warranting the need for effective therapies that target PDEs selectively. 
This short review focuses on the importance of activating compartmentalised cAMP 
signalling by displacing the PDE component of signalling complexes using cell 
permeable peptide disrupters 
 
Perspectives 
 
Importance to the field: As PDEs tend to have highly conserved catalytic domains, 
agents that target the cellular location of this enzyme family rather than the catalytic 
site have the potential to be more specific than conventional PDE inhibitors. This 
should facilitate identification of the role of individual PDE isoforms and hence offer 
novel therapeutic routes to solve aberrant cAMP signalling in disease. 
 
Current thinking: As cAMP is a ubiquitous second messenger that is used to 
transduce signals from many G-protein coupled receptors, specificity of receptor 
function is maintained by the unique spatial and temporal profile of cAMP gradients 
that are formed within the cell following specific receptor activation events. Three-
dimensional cAMP gradients are formed by localised PDE "pools" that are tethered 
in signalling complexes at define cellular locations. Dis-regulated cAMP signalling 
caused by lack of coordination between enzymes that produce, are activated by and 
degrade cAMP can lead to disease. It is possible to rescue cAMP deficits using 
conventional PDE inhibitors that compete with cAMP for the enzyme's catalytic site, 
however a new approach that seeks to displace PDEs from their cellular location is 
being pioneered to get round the problem of "off target" effects that arise from the 
lack of isoform selectivity seen with current pharmacologic approaches. 
 
Future directions: Development of agents that can specifically "unhook" single 
isoforms of PDE from defined signalling complexes at one cellular location is in its 
"proof-of-concept" stage. Disruptor peptides have been used to show that this 
strategy can work in cellular models of disease, however they will have to become 
more "drug-like" before their true potential as therapeutics are realised. 
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Introduction 
Since the initial discovery of cyclic 3’,5’-adenosine monophosphate (cAMP) over 60 
years ago, extensive research has shown cAMP to be a master regulator of 
intracellular signalling pathways 1,2.  cAMP is a ubiquitously utilised second 
messenger that is synthesised by membrane-bound and soluble adenylate cyclase 
(AC) enzymes 3. cAMP mediates it’s myriad of cellular responses through cAMP-
effector proteins: protein kinase A (PKA), exchange protein directly activated by 
cAMP (EPAC), cyclic nucleotide activated ion channels (CNGC) and Popeye domain 
containing proteins (POPDC) 4. These proteins are responsible for regulating 
signalling cascades, which play crucial roles in cellular proliferation and 
differentiation, apoptosis, gene expression and metabolism. Advancements in cAMP 
detection methodology has reinforced the existence of discrete cAMP nanodomains 
that are spatially restricted within subcellular compartments 5,6.  
 
Data from these novel cAMP reporters have bolstered the concept that specific 
physiological outcomes directed by individual G-protein coupled-receptors are 
dependent upon compartmentalised cAMP signalling that is shaped by localised 
“pools” of PDE. Fine-tuning of cAMP dynamics in space and time is achieved by 
coordination between AC and phosphodiesterase (PDE) enzyme activity 5. PDEs are 
the only known enzymatic means of degrading cyclic nucleotides and hence PDEs 
are recognised for their ability to maintain homeostatic responsiveness of localised 
cAMP-effector proteins by maintaining cAMP levels below the threshold of activation 
7. In this context it is easy to conceptualise that aberrant localisation of PDE activity 
leads to unequilibrated cAMP signalling that results in disease. Unsurprisingly, this 
has led to the development of multiple pharmacological agents with the ability to 
target PDE activity directly via inhibition 8,9 or activation 10. 
The following review will discuss the therapeutic benefit of targeting individual PDE – 
protein complexes, focussing on the development of novel cell-permeable peptides 
that disrupt PDE signalosomes in order to reshape cAMP signal-specific responses 
in cells. 
 
PDE Overview: Structure, function and compartmentalisation 
 
Phosphodiesterases are a diverse super-family of cyclic nucleotide degrading 
enzymes that catalyses the hydrolysis of cAMP/cGMP into inactive 5’ AMP/GMP. 
Mammalian PDEs consist of 11 subtypes (PDE1-11), encoded by 21 genes that give 
rise to over 100 PDE isozymes (e.g. PDE4A-D, PDE7A-B, PDE8A-B, etc.)11. PDE 
subtypes are classified according to their structure, affinity for cAMP and/or cGMP, 
catalytic activity and mechanism of action11. Structurally, PDEs share a conserved 
catalytic region and form homo-dimers; with the exception of PDE6 holo-enzymes 
that typically form heterodimers under physiological conditions 57. Interestingly, 
individual PDE isoforms contain unique amino-terminal subdomains and N-terminal 
regions that determine subcellular location via interaction with membranes and key 
protein partners within signalosomes. Of the 11 families, PDE4, 7 and 8 specifically 
hydrolyse cAMP, PDE5, 6 and 9 hydrolyse cGMP and PDE1-3, 10 and 11 hydrolyse 
both cAMP and cGMP. Further detail on individual PDEs expression, structural, 
functional and pharmacological properties can be found in several excellent reviews 
9,12.  
Compartmentalisation of PDEs is crucial to their function and enables precise 
spatiotemporal control of cAMP dynamics5. Formation of unique signalosomes, in 
which combinations of PDEs and cAMP-effector proteins form protein-complex 
interactions with each other and/or with membrane bound proteins (e.g. β-adrenergic 
receptors, adenylate cyclase), scaffolding proteins (e.g. AKAPs, β-arrestin, RACK1) 
and/or other cAMP-effector protein substrates (e.g. HSP20, C-Raf), is pivotal to the 
regulation of related downstream signalling pathways 13,14. A prime example of how 
compartmentalised PDEs tightly regulate cAMP dynamics is the tethering of both 
PKA and PDE4D3 to the mAKAP scaffolding protein at the perinuclear compartment. 
The mAKAP “pool” of PDE4D3 exerts negative feedback control that attenuates PKA 
activity following an increase in cAMP. Thus, PDE4D3 acts as a cAMP ‘sink’ that 
maintains local control of PKA activity through degradation of cAMP surrounding this 
signalosome15. 
PDE signalosomes as therapeutic targets 
Research into how recruitment of individual PDE isoforms within distinct 
signalosomes, sculpts cAMP gradients has led to the identification of over 100 
unique PDE-specific protein-interactions9. Subsequently, this prompted the 
realisation that by targeting single PDE-protein interactions, precise regulation of 
individual cAMP nanodomains could be achieved16 . Studies looking at the cAMP-
specific PDE4 family (primarily within the cardiovascular system) have helped 
delineate some of the underlying mechanisms involved with PDE 
compartmentalisation 17,18. PDE4 is arguably the largest family of PDE enzymes 
encoded by four genes (PDE4A-D), giving rise to over 20 isoforms, which are 
ubiquitously expressed throughout many tissues. PDE4 isoforms specific functions 
are largely determined by their subcellular location, post-translational modifications 
and interaction with signalling proteins 7.  
With regard to cellular localisation, PDE4 isoform-specific N-terminal sequences act 
as a ‘post-code’ for PDE4 localisation directing each unique PDE4 – protein complex 
association19. Other regions may also confer protein-protein interactions 20. 
Importantly, multiple non-redundant roles of the same PDE4 isoform (e.g. PDE4D5) 
have been identified, where-by a single isoform exists in more than one signalosome 
at different locations within the same cell 19,21-23. In this context, the advantages of 
agents that target single “pools” of one enzyme rather than the activity of entire 
global PDE4 “pool” become clear. Pharmacological inhibition by targeting the active 
site of PDE4 or even genetic ablation via siRNA or displacement using transfected 
dominant negative catalytically dead isoforms cannot achieve geographical isolation 
of single isoforms tethered at one cellular site. Disruption of individual PDE protein-
protein interactions is the only option to achieve such specificity 16. 
Some key examples of PDE4-protein interactions include: PDE4A4/5 – P75 NTR 
24,25, PDE4B – DISC1 26, PDE4D5 – Integrin α5 27, PDE4D5 – β-arrestin 22, PDE4D5 
– RACK1 28, PDE4D5 – HSP20 29 and PDE4D8 – β1-adrenergic receptors 30. Many 
of these PDE-protein complexes are implicated in the progression of disease, and 
therefore represent viable therapeutic targets. We highlight 2 examples below, 
namely PDE4A4/5 – P75 NTR complex and the PDE4D5 – Integrin α5 complex. 
P75 NTR, through sequestering of other signalling mediators, inhibits fibrin 
degradation; a process crucial to promoting extracellular matrix (ECM) remodelling 
and tissue repair following insult 24. Direct interaction between P75 NTR and 
PDE4A5 (with binding sites identified in the UCR2 and catalytic domain regions) led 
to the realisation that local cAMP degradation attenuated PKA-mediated activation, 
impairing P75 NTR driven tissue repair mechanisms. This in turn suppressed tissue 
plasminogen activator (tPA) and potentiated plasminogen activator inhibitor-1 (PAI-1) 
activity, promoting scar formation and inhibiting ECM remodelling. Further, p38 
MAPK inflammatory signalling was found to regulate this interaction as MAPKAPK2 
(MK2) phosphorylation of PDE4A5 (a p38 downstream signalling kinase) 
upregulated its association with P75 NTR 25. Targeting of the PDE4A5 – P75 NTR 
complex represents a potentially promising therapeutic target in treating fibrinolysis 
associated with COPD and atherosclerosis.  
Increased fibronectin (FN) associated inflammatory signalling has been identified as 
an early event in the progression of atherosclerosis. Interestingly, the cytoplasmic 
region of Integrin α5 (subunit of the major α5β1 FN receptor) was recognised as a 
direct binding partner of PDE4D5, binding within its UCR2 region (as seen with P75 
NTR – PDE4A5) 27. PDE4D5 degrades the cAMP nanodomain surrounding integrin 
α5, promoting FN-driven atherosclerotic pro-inflammatory signalling. Blocking the 
integrin α5 pathway attenuated PDE4D5 binding, suppressed endothelial pro-
inflammatory signalling, reduced plaque size without impairing plaque stability and 
improved recovery in an animal model of atherosclerosis 27,31. Thus, targeted 
disruption of PDE4D5 – Integrin α5 seems to be a promising strategy for the 
treatment of coronary/peripheral artery disease. 
Targeted disruption of PDE protein complexes 
Effective therapies aimed at regulating cyclic nucleotide dynamics through targeting 
the activity of PDE families has driven clinical success and regulatory approval of 
several family selective PDE inhibitors, with dozens in clinical trials and even more in 
pre-clinical/early stage development 9,32. Of the 11 PDE families, clinically approved 
inhibitors are limited to PDE3 (milrinone and cilostazol), PDE4 (roflumilast and 
apremilast) and PDE5 (sildenafil, vardenafil, tadalafil and avanafil), as well as other 
non-selective PDE inhibitors (theophylline and caffeine). Further detail regarding the 
actions of PDE-selective inhibitors and related clinical indications/targets are 
extensively covered in a recent Nature review58.  Despite the clinical achievements 
of many of these small molecule inhibitors, disappointing off-target side effects have 
restricted their use as efficient treatments. These limitations are demonstrated by 
roflumilast, a second-generation PDE4 selective inhibitor for the treatment of severe 
chronic obstructive pulmonary disease (COPD)33. Although this drug is a highly 
potent and effective PDE4 inhibitor, roflumilast systemically targets all PDE4A-D 
isoforms equally. Consequently, patients taking this inhibitor commonly experience 
concerning side-effects including diarrhoea, nausea, headaches, emesis, 
pancreatitis and weight loss.  
One current strategy focussed on decreasing the risk – benefit ratio of selective PDE 
inhibitors is aimed at targeting individual PDE – protein complexes and displacing 
specific PDE isoforms from signalosomes – as opposed to direct inhibition of the 
catalytic site 9,16,34. This approach is believed to overcome the non-selective (for 
isoforms of same family) nature of current PDE inhibitors and reduce unwanted side-
effects through highly selective targeting. Extensive research in this area has utilised 
novel techniques of disrupting specific PDE4 isoforms, including generation of 
catalytically inactive ‘dead’ PDE4 isoforms 35,36, siRNA silencing 37, murine 
knockout/knockdown models 38 and PDE429-protein complex peptide disrupter 
interference. These techniques have provided invaluable insight into the individual 
functions of uniquely tethered PDE4 isoforms. However, as previously stated, each 
approach (excluding peptide disrupter interference), is disadvantaged by the fact that 
they target multiple subpopulations of the same isoform or subfamily. As individual 
subpopulations of PDE4 have multiple non-redundant roles within the same 
cell/tissue, investigating their niche functions become difficult using these 
techniques. This limitation is overcome through targeting pools of defined PDE-
protein complex interactions with novel cell permeable peptide disrupters 16. 
Developing novel PDE peptide disrupters 
Accurate mapping of PDE-protein interfaces, and subsequent design of novel 
peptide disrupters, has been facilitated through the utilisation of high-throughput 
peptide microarray technology 39,40. Briefly, linearised synthetic peptides (up to 25 
amino acids (aa) in size), spanning the entire length of a protein of interest (e.g. 
PDE4D5), are covalently ‘spotted’ onto an immobilised cellulose support. Purified 
recombinant protein (i.e. a validated PDE4D5 binding partner) is then overlaid onto 
the microarray and a far western immunoblot is carried out to identify existing 
continuous and/or non-continuous binding sites. Positive ‘spots’ detail binding 
sequences that can be further analysed through rational substitution and/or peptide 
truncation analyses to identify key ‘hot spot’ regions and minimum binding 
sequences. As peptides are linearised, and therefore do not display their natural 
secondary and tertiary structures, mutagenesis studies can be deployed to confirm 
binding regions and to further investigate their significance to PDE function and 
localisation. Incidentally, peptide microarray technology not only offers a rapid and 
powerful screening tool for the identification of key interaction domains between 
protein-protein interactions within select PDE signalosomes, but can also be used to 
rationally design short sequence peptides capable of disrupting specific PDE-protein 
complexes in vivo 41. This approach is by far the most selective method of PDE 
signalosome inhibition, targeting only the localisation of a single “pool” of individual 
PDE isoforms and leaving all other PDEs (including PDEs of the same isoform at 
different locations within the same cell) untouched.  
Cell permeable peptide disrupters of PDE signalosomes 
Peptide therapeutics offer a highly diverse pool of potential drug candidates that 
possess many advantages compared with traditional small-molecule drugs 42. 
Peptides tend to be highly potent and efficacious, demonstrating high specificity and 
selectivity toward their target and leading to fewer off-target side effects. Additionally, 
their natural characteristics result in fewer immunogenic responses, lower toxicity 
and improved tolerability. Classical disadvantages related with peptides therapeutics 
(i.e. cell membrane impermeability, susceptibility to degradation and poor oral 
availability) are slowly being addressed, with significant improvements in cell-
penetrating chaperones and physicochemical modifications empowering their use 
within the clinic 43.  
Peptide microarray mapping of the putative binding domains between PDE4D5 – 
RACK1, PDE4D5 – β-arrestin39 and PDE4D5 – EPAC1 complex 44 has validated the 
concept of utilising cell permeable peptide disrupters as selective inhibitors of 
distinctly compartmentalised PDE signalosomes that can even contain the same 
isoform. This strategy has been further ratified, through targeted disruption of 
complexes such as PDE4D5 – HSP20 29 and PDE8A – C-Raf 45.  These protein-
protein interactions represent potentially efficacious therapeutic targets in the 
treatment of cardiovascular disease, cancer and autoimmune disease and will be 
discussed below. 
 
PDE4D5 – HSP20 (Figure 1) 
Small heat shock protein 20 (HSP20) is a highly ubiquitous molecular chaperone that 
is upregulated following cellular stress in order to trigger a broad-spectrum of 
protective actions in the context of cardiovascular disease, neurodegenerative 
disease and cancer 46. Under basal physiological conditions, HSP20 remains 
inactive. However, cellular stressors promote an upregulation of active HSP20 
through phosphorylation at Ser16 via PKA (in some circumstances, PKG and PKD) 
47,48. Tight proximity between HSP20 and PKA is maintained within the cytoplasm 
through complex interactions with the AKAP-Lbc scaffolding protein, facilitating 
HSP20’s protective actions 49. Although the phosphorylation of HSP20 has been 
shown to be protective against several diseases, the chaperone’s qualities have 
predominantly been characterised within the cardiovascular system, particularly in 
settings of chronic β-adrenergic induced stimulation, ischaemia/reperfusion (I/R) 
injury and heart failure 47. Transgenic overexpression of HSP20, and expression of 
constitutively active HSP20 mutants (S16D), safeguard against cardiac remodelling 
and attenuate apoptotic signalling in both ex vivo and in vivo models of cardiac 
hypertrophy and I/R injury 50,51. Effects not seen following expression of a phospho-
null HSP20 mutant (S16A).  
 Complimentary co-immunoprecipitation, ELISA and peptide microarray 
techniques identified PDE4D5 as a direct binding partner of HSP20, mapping the 
interaction to within aa residues 461 – 495 of PDE4D5s conserved catalytic domain 
29. The PDE4D “pool” associated with HSP20 shapes the cAMP nanodomain 
surrounding the chaperone, maintaining it in inactive unphosphorylated aggregates. 
Directly inhibiting PDE4, and/or saturating local PDE4 nanodomains through 
persistent cAMP production, can overcome PDE-mediated HSP20 inhibition 
(mentioned above). Interestingly, a rationally designed 25mer stearylated cell 
permeable peptide (bs906), based on the PDE4D5 binding domain (E468-K492), can 
act as a novel inhibitor targeting the disruption of PDE4D5 – HSP20 29. Bs906 
effectively displaced PDE4D5 from HSP20 and potentiated PKA-phosphorylation of 
HSP20 at Ser16 (See Figure 1). As a result, bs906 was found to attenuate ANP gene 
expression (hypertrophy marker), hypertrophic remodelling and cardiac fibrosis, 
whilst improving left-ventricular function in an aortic-banded heart failure mouse 
model 41. Cardioprotective effects were not found in mice treated with scrambled 
peptide disrupter sequences.  
 
PDE8A – C-Raf (Figure 2) 
Discovery of the PDE8A – C-Raf interaction added a new level of complexity to 
cross-talk between cAMP-PKA and RAS-RAF-MEK-ERK signalling axes 52. In short, 
PDE8A could be detected in complex with C-Raf (Raf-1) and influence the activity of 
the kinase 45. PKA phosphorylation of C-Raf at Ser259 inhibits it, attenuating 
downstream MEK-ERK signalling. PDE8A binds C-Raf with high picomolar affinity 
(<61pM), protecting C-Raf from PKA-mediated inhibition. This protection is increased 
following overexpression of PDE8A in HEK293 cells. Conversely, expression of a 
catalytically inactive PDE8A mutant displaced the endogenous active PDE pool, 
suppressing ERK activation through a marked increase in C-Raf phosphorylation 45. 
This concept was further ratified in mouse and drosophila PDE8 knock-out models. 
Peptide microarray mapping identified a key C-Raf binding region within the 
conserved PDE8A catalytic domain (N442 – I476), narrowing the minimum required 
binding site down to 9 amino acids (R454 – Y461). Subsequent rational design of a 
stearylated PDE8A peptide (R454 – T465) convincingly disrupted the endogenous 
PDE8A – C-Raf interaction, potentiating inhibitory C-Raf phosphorylation and 
suppressing ERK activation. This effect was not observed with a scrambled control 
peptide45. As C-Raf activity plays a central role in the regulation of mechanisms 
involved in multiple cancers53, and as PDE8A is thought to make up only ~5% of 
total PDE8 expression within cells, targeted disruption of PDE8A – C-Raf has 
potential as a highly selective anti-cancer treatment. 
 Optimisation of the PDE8A peptide disrupter, through C-terminal conjugation 
with a novel HOXD12 homeodomain protein-based cell penetrating peptide (Cell 
Porter®; Portage Pharmaceuticals Limited), validated the therapeutic potential of 
disrupting the PDE8A – C-Raf complex in B-Raf inhibitor resistant melanoma 54 (See 
Figure 2). Co-treatment with PDE8A – Cell Porter® peptide (PPL-008C) robustly 
suppressed B-Raf inhibitor (PLX4032/Vemurafenib) induced paradoxical ERK 
activation and attenuated cell proliferation in MM415 human malignant melanoma 
cells (NRAS Q61L, KRAS WT, BRAF WT). Moreover, PPL-008C monotherapy 
demonstrated a rapid and long-lasting abrogation of ERK activation in an MM415 
xenograft mouse model 54.  As gain-of-function RAS mutations exist in over 25% of 
human cancers 55, and with C-Raf activity inhibition being recognised as a novel 
target in overcoming B-Raf inhibitor resistant cancer, therapeutic use of PPL-008C is 
currently being investigated in mutant RAS pancreatic, lung and colorectal cancers. 
 Interestingly, a recent report using original PDE8A-stearylated peptide, was 
found to inhibit the adhesion and migration of T-effector cells to brain endothelial 
cells in an auto-immune mouse model of multiple sclerosis56. Disruption of this 
PDE8A signalosome produced a more potent effect than PF-04957325, a highly 
selective PDE8 enzyme inhibitor. These findings add to the therapeutic value of 
attenuating ERK activity through PDE8A – C-Raf disruption in the setting of 
inflammatory disease. Follow-up studies using the PDE8A-Cell Porter® peptide are 
underway.   
Conclusion 
Family selective small molecule PDE inhibitors can be limited by their indiscriminate 
targeting of multiple PDE-signalosomes within non-target tissues, resulting in dose-
limiting side-effects. Development of novel and highly selective cell permeable 
peptide disrupters that target individual PDE-protein complexes within defined 
cellular compartments have the unique ability to reshape cAMP gradients on a 
nanoscale. Targeted disruption of PDE4D5 – HSP20 and PDE8A – C-Raf exemplify 
the therapeutic potential of such an approach in the setting of cardiovascular 
disease, cancer and inflammation. Rational design of peptide disrupters targeting 
other key-disease linked to PDE-protein complexes (e.g. PDE4D5 – Integrin α5 27 
and PDE4A5 – P75 NTR24) will help characterise novel functions of defined PDE 
signalosomes and offer a proof-of-concept of therapeutic approaches that seek to 
displace localised pools of specific PDEs.  
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Figure 1: Potentiating HSP20-mediated cardioprotection through targeted 
disruption of PDE4D5 – HSP20. 
A [LEFT]: PDE4D5 – HSP20 interact at the site of AKAP-Lbc. β-adrenergic receptor 
(AR) stimulation upregulates cAMP production, activating PKA. PDE4D5 degrades 
cAMP surrounding HSP20, attenuating PKA-mediated serine 16 
phosphorylation/HSP20 activation. A [RIGHT]: Targeted disruption with stearylated 
PDE4 peptide (bs906) binds HSP20, displacing endogenous PDE4D5. PDE4D5 – 
HSP20 disruption exposes HSP20 Ser16 to PKA phosphorylation, potentiating 
HSP20 activity (represented as a dimer) and its subsequent cardioprotective actions. 
B: Simple schematic of PDE4D5 (long PDE4D isoform) protein structure. UCR1/2, 
upstream conserved regions 1/2; LR1/2, linker regions 1/2; Catalytic domain with 
cAMP binding pocket. C: Simple schematic of HSP20 protein structure. Ser16, 
serine 16 residue; conserved α-crystallin domain, flexible C-terminal region 
 
Figure 2: Combined inhibition of B-Raf/C-Raf heterodimers in B-Raf inhibitor 
resistant cancer.  
A [LEFT]: B-Raf inhibition leads to the paradoxical activation of C-Raf through a 
negative feedback RAS-driven switch. PDE8A degrades cAMP, protecting C-Raf 
from PKA-mediated serine 259 inhibitory phosphorylation. Both allow the 
continuation of tumour growth. A [RIGHT]: PPL-008C (PDE8A-Cell Porter®) peptide 
disrupter displaces endogenous PDE8A – C-Raf protein complex, exposing C-Raf – 
serine 259 to inhibitory PKA phosphorylation. Combined B-Raf and C-Raf inhibition 
suppresses MEK-ERK driven oncogenesis. B: Simple schematic of PDE8A 
monomeric protein structure. REC, signal regulatory domain; PAS, PAS domain. 
Catalytic domain with cAMP binding pocket C: Simple schematic of C-Raf 
monomeric protein structure. RBD, Ras binding domain; s259, inhibitory serine 
residue 259; NKD and CKD, N-terminal and C-terminal lobes of catalytic tyrosine 
kinase domain. 
 
 
 
